XT
KYTX icon

XTX Topco’s Kyverna Therapeutics KYTX Stock Holding History

XTX Topco’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,282
Closed -$219K – 4486
2025
Q4 		$219K Sell
23,282
-25,825
-53% -$192K 0.01% 2330
2025
Q3 		$295K Buy
49,107
+14,168
+41% +$56.6K 0.02% 1513
2025
Q2 		$107K Buy
+34,939
New +$86.4K ﹤0.01% 1873
2025
Q1 		– Sell
-43,949
Closed -$164K – 3221
2024
Q4 		$164K Sell
43,949
-8,843
-17% -$42.4K 0.01% 1628
2024
Q3 		$258K Sell
52,792
-30,494
-37% -$235K 0.02% 1287
2024
Q2 		$625K Buy
+83,286
New +$1.27M 0.05% 549

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

XTX Topco's KYTX Position: Q1 2026 in Review

XTX Topco sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 23,282 shares — an estimated $219K sold.

XTX Topco first reported a position in KYTX in Q2 2024 and held it in 6 quarters. The position peaked at $625K in Q2 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • XTX Topco reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 23,282 Kyverna Therapeutics shares in Q1 2026, an estimated $219K.
  • XTX Topco first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 6 quarters.
  • XTX Topco's Kyverna Therapeutics position peaked at $625K in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.